Nanogea, a nano-biotech
company focused on commercializing the industry's most sensitive single molecular
detection platform, is pleased to announce today that Dr. C. Thomas Caskey and
Dr. Saul Tendler have joined its scientific advisory board.
Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr.
Caskey presently serves as Director and Chief Executive Officer of the Brown
Foundation Institute of Molecular Medicine, a research institute that seeks
to investigate the cause of human diseases at the cellular and molecular levels
using DNA and protein technologies to expose disease mechanisms. He is a former
founding Director and CEO of Cogene Biotech Ventures, venture capital funds
designed to support early-stage biotechnology and life science companies. Dr.
Caskey is a former SVP for Res. at Merck and Trustee and President of the Merck
Genome Res. Inst. as well as an Ex-Chief of Section of Medical Genetics and
Professor of Medicine and Biochemistry, Baylor College of Medicine. He sits
on the boards of Essex Woodlands Health Ventures, Luminex, Odyssey Thera, En
Vivo, Metabolon, Genome Canada, LabCorp. of America, and Vice Chair of Genome
Canada. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science
of Texas (President of TAMEST 2004-05), a member of the National Academy of
Sciences, and the Institute of Medicine. Dr. Caskey received his medical doctorate
from Duke University. He is Board certified in Internal Medicine, Clinical Genetics,
Metabolic Diseases, and Molecular Diagnostics.
Dr. Saul Tendler is Pro-Vice-Chancellor, Professor of Biophysical Chemistry
and Head of the School of Pharmacy, University of Nottingham. His expertise
is in the field of biophysical chemistry, with a particular focus on analysis
of biomolecular systems and their interactions. Dr. Tendler is a Fellow of the
Royal Society of Chemistry, and was designated a Fellow of the Royal Pharmaceutical
Society of Great Britain in 2000. Dr. Tendler received his Ph.D. from the University
of Aston and his Bachelors of Science (First Class Honours) in Pharmacy at the
University of Manchester.
"We are delighted to have a distinguished panel of advisors such as Drs.
Caskey and Tendler," said Mr. David Sun, President and CEO of Nanogea,
"Their extraordinary expertise and background will help guide Nanogea's
research and development in the foreseeable future as we expedite our development
effort to commercialize our first clinical application for CML (Chronic Myelogeous
Leukemia) detection, based on our proprietary NanoCone™ chemistry and
NE-AFM™ platform."
Posted October 9th, 2009
